Results 41 to 50 of about 29,030 (239)

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy [PDF]

, 2006
Background: Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any other treated patients.
Barkhof, F., Clifford, D.B., Curfman, B., Fahle, G., Fischer, S., Habil, M., Hou, J., Jäger, H.R., Major, E.O., Miszkiel, K., Mueller-Lenke, N., Radue, E.-W., Ryschkewitsch, C., Sanchez, E., Yousry, T.A.   +14 more
core   +1 more source

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis

Multiple Sclerosis, 2021
Background: REFINE was an exploratory, dose- and frequency-blinded, prospective, randomized, dose-ranging study in relapsing–remitting multiple sclerosis (RRMS) patients.
M. Trojano, L. Ramió-Torrentá, L. Grimaldi, C. Lubetzki, S. Schippling, K. Evans, Zheng Ren, K. Muralidharan, S. Licata, Arie R. Gafson   +9 more
semanticscholar   +1 more source

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2023
Background: Natalizumab is a highly effective monoclonal antibody for the treatment of multiple sclerosis (MS), which can diffuse in different anatomical compartments, including cerebrospinal fluid (CSF) and milk.
Ilaria Callegari, Mika Schneider, Vera Aebischer, Margarete M. Voortman, Undine Proschmann, Tjalf Ziemssen, Raija Lindberg, Bettina Fischer-Barnicol, Michael Khalil, Ludwig Kappos, Jens Kuhle, Nicholas S.R. Sanderson, Tobias Derfuss   +12 more
doaj   +1 more source

The still under-investigated role of cognitive deficits in PML diagnosis [PDF]

, 2017
Background: Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in PML diagnosis is still under ...
Amato, Maria Pia, Artusi, Carlo Alberto, Bandini, Fabio, Barcella, Valeria, Bertolotto, Antonio, Bresciamorra, Vincenzo, Capobianco, Marco, Capra, Ruggero, Cavaletti, Guido, Cavalla, Paola, Centonze, Diego, Clerico, Marinella, Cordioli, Cinzia, Cosottini, Mirco, D'Aleo, Giangaetano, de Riz, Marilena, De Rossi, Nicola, Deotto, Luciano, Durelli, Luca, Falcini, Mario, Ferrari, Ernesta, Fusco, Maria Luisa, Gasperini, Claudio, Gerevini, Simonetta, Ghezzi, Angelo, Grimaldi, Luigi, Guidotti, Mario, Laroni, Alice, Lugaresi, Alessandra, Mattioli, Flavia, Moiola, Lucia, Naldi, Paola, Pane, Chiara, Perrone, Patrizia, Pizzorno, Matteo, Pozzilli, Carlo, Prosperini, Luca, Rezzonico, Monica, Rovaris, Marco, Salemi, Giuseppe, Salvetti, Marco, Santuccio, Giuseppe, Scarpazza, Cristina, Scarpini, Elio, Sessa, Edoardo, Solaro, Claudio, Tabiadon, Giulia, Tortorella, Carla, Trojano, Maria, Valentino, Paola   +49 more
core   +2 more sources

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

PLoS ONE, 2012
In multiple sclerosis (MS), treatment with the monoclonal antibody natalizumab effectively reduces the formation of acute lesions in the central nervous system (CNS).
Lars Börnsen, Jeppe Romme Christensen, Rikke Ratzer, Annette Bang Oturai, Per Soelberg Sørensen, Helle Bach Søndergaard, Finn Sellebjerg   +6 more
doaj   +1 more source

A controlled trial of natalizumab for relapsing multiple sclerosis. [PDF]

, 2003
Background: In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving activated lymphocytes and monocytes.
Blumhardt, LD, Dalton, CM, Int Natalizumab Multiple Sclerosis, Khan, OA, Libonati, MA, Miller, DH, Miszkiel, KA, O'Connor, PW, Rice, GPA, Sheremata, WA, Willmer-Hulme, AJ   +10 more
core   +1 more source

Natalizumab para la esclerosis múltiple remitente-recurrente

Neurología, 2011
Resumen: Introducción: Natalizumab es un anticuerpo monoclonal inhibidor de la migración leucocitaria a través de la barrera hematoencefálica, autorizado para el tratamiento de la esclerosis múltiple remitente-recurrente. Objetivo: Realizar una revisión
A. Horga, M. Tintoré
doaj   +1 more source

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring

Frontiers in Immunology, 2020
Multiple sclerosis is a chronic demyelinating disease of the central nervous system (CNS) with an autoimmune component. Among the recent disease-modifying treatments available, Natalizumab, a monoclonal antibody directed against the alpha chain of the ...
K. Khoy, D. Mariotte, G. Defer, Gautier Petit, O. Toutirais, B. Le Mauff   +5 more
semanticscholar   +1 more source

Natalizumab for relapsing-remitting multiple sclerosis

Neurología (English Edition), 2011
Introduction: Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
A. Horga, M. Tintoré
doaj   +1 more source

Severe cytomegalovirus gastritis during natalizumab-mediated immunosuppression [PDF]

, 2017
We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently developed severe cytomegalovirus gastritis.
Hassan, Adil, Hassan, Anjum, Hassan, Tariq, Persaud, Stephen P   +3 more
core   +2 more sources